Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28655739 | 0.76 | ALDH1A1 (0.41) | ALDH1A1TDP1TSHRMEN1LMNA | |
| SCHEMBL11903057 | 0.74 | — | — | |
| SCHEMBL265274 | 0.70 | — | — | |
| SCHEMBL4122875 | 0.67 | — | — | |
| SCHEMBL28487765 | 0.67 | ALDH1A1 (0.32) | ALDH1A1TDP1 | |
| SCHEMBL9452676 | 0.67 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHRMEN1LMNA | |
| SCHEMBL28280677 | 0.67 | TSHR (0.32) | ALDH1A1TSHR | |
| SCHEMBL9452677 | 0.67 | ALDH1A1 (0.41) | ALDH1A1TDP1TSHRMEN1LMNA | |
| SCHEMBL12341097 | 0.67 | ALDH1A1 (0.46) | ALDH1A1TDP1TSHRMEN1LMNA | |
| SCHEMBL20641014 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56005457-A | — | — | None | — | — | JP | disclosed |
| JP-56008372-A | — | — | None | — | — | JP | disclosed |
| CN-113563306-B | Preparation method of 2- (4-phenoxyphenyl) -6- (piperidine-4-) nicotinamide | 新发药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-113563306-A | Preparation method of 2- (4-phenoxyphenyl) -6- (piperidine-4-) nicotinamide | 新发药业有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-7320994-B2 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1501809-B1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| CN-1312136-C | Triazole derivatives as tachykinin receptor antagonists | LILLY CO ELI (US) | 2007-04-25 | — | — | CN | disclosed |
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| CN-1646502-A | Triazole derivatives as tachykinin receptor antagonists | LILLY CO ELI (US) | 2005-07-27 | — | — | CN | disclosed |
| EP-1501809-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6004982-A | SIDE EFFECT REDUCTION; SCHIZOPHRENIA | HOECHST MARION ROUSSEL, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| WO-1998034933-A1 | (4-PIPERIDINYL)-1H-2-BENZOPYRAN DERIVATIVES USEFUL AS ANTIPSYCHOTIC AGENTS | HOECHST MARION ROUSSEL, INC. (US) | 1998-08-13 | — | — | WO | disclosed |
| CN-1190390-A | Nitric oxide synthase inhibitors derived from cyclic amidines | SEARLE & CO (US) | 1998-08-12 | — | — | CN | disclosed |
| CN-1189823-A | Cyclic amidino formulations useful as nitric oxide synthase inhibitors | SEARLE & CO (US) | 1998-08-05 | — | — | CN | disclosed |
| EP-0824523-A1 | NITRIC OXIDE SYNTHASE INHIBITORS DERIVED FROM CYCLIC AMIDINES | G.D. Searle & Co. (US) | 1998-02-25 | — | — | EP | disclosed |
| EP-0821674-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996035677-A1 | NITRIC OXIDE SYNTHASE INHIBITORS DERIVED FROM CYCLIC AMIDINES | G.D. SEARLE & CO. (US) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996033175-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-10-24 | — | — | WO | disclosed |
| JP-S568372-A | ISOXAZOLINES | DAI ICHI SEIYAKU CO LTD | 1981-01-28 | — | — | JP | disclosed |
| JP-S565457-A | THIENAMYCIN INTERMEDIATE | DAI ICHI SEIYAKU CO LTD | 1981-01-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | TACR1, TACR2, BDKRB1 | ALDH1A1 1408/4885TDP1 3181/4885TSHR 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.